Post-vaccination and post-infectious immune response against new coronavirus infection on the background of obesity and overweight

In the fall of 2019, global health was confronted with a new RNA virus — severe acute respiratory syndrome coronavirus 2 SARS-CoV-2. Against the background of the rapid spread of infection, research centers around the world began to develop specific vaccines against COVID-19, using the accumulated experience and empirical data on the stereotypes of the structure and physiology of other viral agents of this family (severe acute respiratory syndrome virus (SARS) and Middle East respiratory syndrome (MERS). However, even before the development of anti-COVID vaccines, it was suggested that they are probably less effective in a number of individuals, in particular, in people who are overweight or obese. This hypothesis arose on the basis of past studies using vaccines for other purposes in this categories of people, as well as in numerous experiments on mice, thanks to which scientists came to the conclusion that, due to an excess amount of adipose tissue in the body, there is a state of a permanent inflammatory process, some immune dysfunction, and, as a result, a reduced local and systemic response. resistance against bacterial and viral agents.

In this literature review, using current publications obtained by searching for “covid-19 vaccination and obesity” and “vaccination and obesity” in the PubMed databases and “covid-19 vaccination and obesity” and “vaccination and obesity” in the e- Library discusses changes in the immune response both to infection itself and to immunization in the presence of overweight or obesity.

1. WHO [Internet] 2021. Fact sheet on overweight and obesity: World Health Organization. [cited 16.02.2023] Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

2. Rychter AM, Zawada A, Ratajczak AE, e Should patients with obesity be more afraid of COVID‐19? Obes Rev. 2020;21(9):e13083. doi: https://doi.org/10.1111/obr.13083

3. Karlsson EA, Beck MA. The burden of obesity on infectious disease. Exp Biol Med. 2010;235(12):1412-1424. doi: https://doi.org/10.1258/ebm.2010.010227

4. Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020;395(10224):565-574. doi: https://doi.org/10.1016/S0140-6736(20)30251-8

5. Rokkam VRP, Vegunta R, Prudhvi K, et al. “Weighing” the risks and benefits – Thromboprophylaxis challenges in obese COVID-19 patients. Obes Med. 2020;(19):100284. doi: https://doi.org/10.1016/j.obmed.2020.100284

6. Alfaro S, Autrey C, Sen-Crowe B, Elkbuli A. Obesity implications on SARS-CoV-2 infections’ prevalence, hospitalizations, critical care needs, fatalities & vaccination rates: A public health crisis. Ann Med Surg. 2021;(72):103096. doi: https://doi.org/10.1016/j.amsu.2021.103096

7. Croci S, Venneri MA, Mantovani S, et al. The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males. Autophagy. 2022;18(7):1662-1672. doi: https://doi.org/10.1080/15548627.2021.1995152

8. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, et al. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11(1):29. doi: https://doi.org/10.1186/s13293-020-00304-9

9. Helvaci N., Eyupoglu N.D., Karabulut E., et al. Prevalence of obesity and its impact on outcome in patients with COVID-19: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021;12:598249. doi: https://doi.org/10.3389/fendo.2021.598249

10. Izquierdo JL, Ancochea J, Soriano JB. Clinical characteristics and prognostic factors for intensive care unit admission of patients with COVID-19: retrospective study using machine learning and natural language processing. J Med Internet Res. 2020;22(10):e21801. doi: https://doi.org/10.2196/21801

11. O’Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obesity Reviews. 2015;16(1):1-12. doi: https://doi.org/10.1111/obr.12229

12. Sattar N, McInnes IB, McMurray JJV. Obesity is a risk factor for severe COVID-19 infection. Circulation. 2020;142(1):4-6. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.047659

13. Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020;16(7):341-342. doi: https://doi.org/10.1038/s41574-020-0364-6

14. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92(3):347-355. doi: https://doi.org/10.1079/BJN20041213

15. Abaturov A.E. Features of metabolic syndrome in children. Children’s doctor. 2011;4(11):54-61. (In Russ.).

16. Roitberg GE. Metabolic syndrome. Moscow: MEDpress-inform; 2007. (In Russ.).

17. Shpilevskaya YR, Shtonda MV. Metabolic syndrome: modern aspects of diagnosis and treatment. Medical news. 2021;(5):4-8. (In Russ.).

18. Vandanmagsar B, Youm Y-H, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17(2):179-188. doi: https://doi.org/10.1038/nm.2279

19. Westheim AJF, Bitorina AV, Theys J, Shiri‐Sverdlov R. COVID‐19 infection, progression, and vaccination: Focus on obesity and related metabolic disturbances. Obes Rev. 2021;22(10):e13313. doi: https://doi.org/10.1111/obr.13313

20. Pavlova ZSh, Golodnikov II. Obesity = inflammation. Pathogenesis. What does this threaten men with? Medical Bulletin of the South of Russia. 2020;11(4):6-23. (In Russ.). doi: https://doi.org/10.21886/2219-8075-2020-11-4-6-23

21. Nasr M-JC, Geerling E, Pinto AK. Impact of Obesity on Vaccination to SARS-CoV-2. Front Endocrinol (Lausanne). 2022;13(10). doi: https://doi.org/10.3389/fendo.2022.898810

22. Le Bert N, Tan AT, Kunasegaran K, et al. SARS‐CoV‐2‐specific T cell immunity in cases of COVID‐19 and SARS, and uninfected controls. Nature. 2020;584(7821):457‐462. doi: https://doi.org/10.1038/s41586-020-2550-z

23. Karlsson EA, Sheridan PA, Beck MA. Diet-Induced Obesity in Mice Reduces the Maintenance of Influenza-Specific CD8+ Memory T Cells. J Nutr. 2010;140(9):1691-1697. doi: https://doi.org/10.3945/jn.110.123653

24. Frasca D, Ferracci F, Diaz A, et al. Obesity decreases B cell responses in young and elderly individuals. Obesity (Silver Spring). 2016;24(3):615‐625. doi: https://doi.org/10.1002/oby.21383

25. Kosaraju R, Guesdon W, Crouch MJ, et al. B cell activity is impaired in human and mouse obesity and is responsive to an essential fatty acid upon murine influenza infection. J Immunol. 2017;198(12):4738-4752. doi: https://doi.org/10.4049/jimmunol.1601031

26. Painter SD, Ovsyannikova IG, Poland GA. The weight of obesity on the human immune response to vaccination. Vaccine. 2015;33(36):4422-4429. doi: https://doi.org/10.1016/j.vaccine.2015.06.101

27. Kara Z, Akçin R, Demir AN, et al. Risk Factors Influencing Seroconversion after Inactive SARS-CoV-2 Vaccination in People Living with Obesity. Obes Facts. 2022;15(5):648-654. doi: https://doi.org/10.1159/000525555

28. Watanabe M, Balena A, Tuccinardi D, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID‐19 mRNA vaccine. Diabetes Metab Res Rev. 2022;38(1). doi: https://doi.org/10.1002/dmrr.3465

29. Watanabe M, Balena A, Masi D, et al. Rapid weight loss, central obesity improvement and blood glucose reduction are associated with a stronger adaptive immune response following COVID-19 mRNA vaccine. Vaccines. 2022;10(1):79. doi: https://doi.org/10.3390/vaccines10010079

30. Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: A review. Vaccine. 2018;36(36):5350-5357. doi: https://doi.org/10.1016/j.vaccine.2017.07.062